MedTrace Logo

Rifaximin in Patients With Gastroesophageal Variceal Bleeding

NCT02991612 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-05-11

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Conditions

  • Cirrhosis
  • Esophageal and Gastric Varices
  • Gastrointestinal Hemorrhage

Interventions

DRUG

Rifaximin

Patients receive Rifaximin 400mg bid for 2 months

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Shiyao CHEN, M.D. · Zhongshan Hospital, Fudan University, Shanghai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-25
Primary Completion
2017-12-22
Completion
2018-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991612 on ClinicalTrials.gov